These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32206990)

  • 21. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates.
    Li S; Cai Z; Wu X; Holden D; Pracitto R; Kapinos M; Gao H; Labaree D; Nabulsi N; Carson RE; Huang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1544-1554. PubMed ID: 30396272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantifying SV2A density and drug occupancy in the human brain using [
    Koole M; van Aalst J; Devrome M; Mertens N; Serdons K; Lacroix B; Mercier J; Sciberras D; Maguire P; Van Laere K
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):396-406. PubMed ID: 30121895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enabling Efficient Positron Emission Tomography (PET) Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) with a Robust and One-Step Radiosynthesis of a Highly Potent
    Warnier C; Lemaire C; Becker G; Zaragoza G; Giacomelli F; Aerts J; Otabashi M; Bahri MA; Mercier J; Plenevaux A; Luxen A
    J Med Chem; 2016 Oct; 59(19):8955-8966. PubMed ID: 27598384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical PET Studies of [
    Thomsen MB; Schacht AC; Alstrup AKO; Jacobsen J; Lillethorup TP; Bærentzen SL; Noer O; Orlowski D; Elfving B; Müller HK; Brooks DJ; Landau AM
    Mol Imaging Biol; 2020 Oct; 22(5):1290-1300. PubMed ID: 32514885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic Characterization of [
    Becker G; Warnier C; Serrano ME; Bahri MA; Mercier J; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Mol Pharm; 2017 Aug; 14(8):2719-2725. PubMed ID: 28651055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TSPO PET upregulation predicts epileptic phenotype at disease onset independently from chronic TSPO expression in a rat model of temporal lobe epilepsy.
    Bertoglio D; Amhaoul H; Goossens J; Ali I; Jonckers E; Bijnens T; Siano M; Wyffels L; Verhaeghe J; Van der Linden A; Staelens S; Dedeurwaerdere S
    Neuroimage Clin; 2021; 31():102701. PubMed ID: 34090124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [
    Vogler L; Ballweg A; Bohr B; Briel N; Wind K; Antons M; Kunze LH; Gnörich J; Lindner S; Gildehaus FJ; Baumann K; Bartenstein P; Boening G; Ziegler SI; Levin J; Zwergal A; Höglinger GU; Herms J; Brendel M
    Neuroimage Clin; 2023; 39():103484. PubMed ID: 37541098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [
    Zheng C; Holden D; Zheng MQ; Pracitto R; Wilcox KC; Lindemann M; Felchner Z; Zhang L; Tong J; Fowles K; Finnema SJ; Nabulsi N; Carson RE; Huang Y; Cai Z
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1482-1496. PubMed ID: 34761284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands.
    Mercier J; Archen L; Bollu V; Carré S; Evrard Y; Jnoff E; Kenda B; Lallemand B; Michel P; Montel F; Moureau F; Price N; Quesnel Y; Sauvage X; Valade A; Provins L
    ChemMedChem; 2014 Apr; 9(4):693-8. PubMed ID: 24446373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spatio-Temporal Alterations in Synaptic Density During Epileptogenesis in the Rat Brain.
    Mikkelsen JD; Aripaka SS; Bascuñana P; Bankstahl M; Bankstahl JP; Pazarlar BA
    Neuroscience; 2022 Sep; 499():142-151. PubMed ID: 35878719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation and noninvasive kinetic modeling of [
    Bertoglio D; Verhaeghe J; Miranda A; Kertesz I; Cybulska K; Korat Š; Wyffels L; Stroobants S; Mrzljak L; Dominguez C; Liu L; Skinbjerg M; Munoz-Sanjuan I; Staelens S
    J Cereb Blood Flow Metab; 2020 Jun; 40(6):1351-1362. PubMed ID: 31307287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synaptic Terminal Density Early in the Course of Schizophrenia: An In Vivo UCB-J Positron Emission Tomographic Imaging Study of SV2A.
    Onwordi EC; Whitehurst T; Shatalina E; Mansur A; Arumuham A; Osugo M; Marques TR; Jauhar S; Gupta S; Mehrotra R; Rabiner EA; Gunn RN; Natesan S; Howes OD
    Biol Psychiatry; 2024 Apr; 95(7):639-646. PubMed ID: 37330164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hippocampal low-frequency stimulation increased SV2A expression and inhibited the seizure degree in pharmacoresistant amygdala-kindling epileptic rats.
    Wang L; Shi J; Wu G; Zhou F; Hong Z
    Epilepsy Res; 2014 Nov; 108(9):1483-91. PubMed ID: 25205164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A.
    Estrada S; Lubberink M; Thibblin A; Sprycha M; Buchanan T; Mestdagh N; Kenda B; Mercier J; Provins L; Gillard M; Tytgat D; Antoni G
    Nucl Med Biol; 2016 Jun; 43(6):325-32. PubMed ID: 27260773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease.
    Delva A; Van Laere K; Vandenberghe W
    Mov Disord; 2023 Aug; 38(8):1515-1526. PubMed ID: 37382295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.
    Shi J; Zhou F; Wang LK; Wu GF
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered cardiac structure and function is related to seizure frequency in a rat model of chronic acquired temporal lobe epilepsy.
    Powell KL; Liu Z; Curl CL; Raaijmakers AJA; Sharma P; Braine EL; Gomes FM; Sivathamboo S; Macefield VG; Casillas-Espinosa PM; Jones NC; Delbridge LM; O'Brien TJ
    Neurobiol Dis; 2021 Nov; 159():105505. PubMed ID: 34520843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal Positron Emission Tomography Imaging with P2X7 Receptor-Specific Radioligand
    Fu Z; Lin Q; Xu Z; Fu W; Shi D; Cheng Y; Yang T; Liu G; Shi H; Cheng D
    ACS Chem Neurosci; 2022 Dec; 13(23):3512-3522. PubMed ID: 36383137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats.
    Onwordi EC; Halff EF; Whitehurst T; Mansur A; Cotel MC; Wells L; Creeney H; Bonsall D; Rogdaki M; Shatalina E; Reis Marques T; Rabiner EA; Gunn RN; Natesan S; Vernon AC; Howes OD
    Nat Commun; 2020 Jan; 11(1):246. PubMed ID: 31937764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.